Haim Pharma Group

Company Overview

Snapshot

Founded in April 2022 by Miriam O’reilly, Haim Pharma Group operates with 1–10 employees. The company has raised $68,000 across two funding rounds from one investor. In September 2025, Haim Pharma Group received a grant from the Israel Innovation Authority.

Business overview

Haim Pharma Group (HPG) is an Israel-based virtual drug development company focused on advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company's core product is Neurosilin, an oral enteric-coated psilocin capsule designed for stability and controlled release. HPG targets neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), leveraging psilocin’s multimodal mechanisms to slow disease progression. The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Haim Pharma Group's primary focus?

Haim Pharma Group is focused on developing stable and non-hallucinogenic psilocin formulations for neurodegenerative diseases, with a primary emphasis on amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).

What is Neurosilin?

Neurosilin is Haim Pharma Group's pioneering oral enteric-coated psilocin capsule designed for stability and controlled release, intended to treat neurodegenerative diseases through chronic, sub-hallucinogenic dosing.

When was Haim Pharma Group founded?

Haim Pharma Group was founded in April 2022.

What was a key regulatory milestone for Haim Pharma Group?

In July 2025, Haim Pharma Group engaged with the FDA and submitted a briefing package outlining its development strategy and clinical roadmap for its psilocin-based therapies.

What is Haim Pharma Group's operational model?

Haim Pharma Group operates through a virtual model, coordinating with global Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and academic partners for its drug development activities.